EA202191189A1 - Подкожное введение и дозировка антител к c5 для лечения пароксизмальной ночной гемоглобинурии (пнг) - Google Patents
Подкожное введение и дозировка антител к c5 для лечения пароксизмальной ночной гемоглобинурии (пнг)Info
- Publication number
- EA202191189A1 EA202191189A1 EA202191189A EA202191189A EA202191189A1 EA 202191189 A1 EA202191189 A1 EA 202191189A1 EA 202191189 A EA202191189 A EA 202191189A EA 202191189 A EA202191189 A EA 202191189A EA 202191189 A1 EA202191189 A1 EA 202191189A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- pnh
- paroxysmal nocturnal
- nocturnal hemoglobinuria
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Предложены способы клинического лечения пароксизмальной ночной гемоглобинурии (ПНГ), включающие введение пациенту антитела к С5 или его антигенсвязывающего фрагмента, при этом антитело к С5 или его антигенсвязывающий фрагмент вводят (или предназначены для введения) подкожно в соответствии с конкретной клинической схемой применения (т.е. в конкретном количестве дозы и в соответствии с конкретной схемой введения доз). В одном варианте осуществления пациент ранее получал лечение экулизумабом (Soliris).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862752563P | 2018-10-30 | 2018-10-30 | |
PCT/US2019/058846 WO2020092549A1 (en) | 2018-10-30 | 2019-10-30 | Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202191189A1 true EA202191189A1 (ru) | 2021-08-06 |
Family
ID=68621358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202191189A EA202191189A1 (ru) | 2018-10-30 | 2019-10-30 | Подкожное введение и дозировка антител к c5 для лечения пароксизмальной ночной гемоглобинурии (пнг) |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210395352A1 (ru) |
EP (2) | EP3873602B1 (ru) |
JP (2) | JP2022512632A (ru) |
KR (1) | KR20210084533A (ru) |
CN (1) | CN112996561A (ru) |
AU (1) | AU2019370295A1 (ru) |
BR (1) | BR112021008063A2 (ru) |
CA (1) | CA3118282A1 (ru) |
CO (1) | CO2021006290A2 (ru) |
EA (1) | EA202191189A1 (ru) |
IL (1) | IL281990A (ru) |
MX (1) | MX2021004994A (ru) |
WO (1) | WO2020092549A1 (ru) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116194478A (zh) * | 2020-06-24 | 2023-05-30 | 阿雷克森制药公司 | 皮下(sc)施用抗c5抗体治疗补体相关病症 |
EP4281472A1 (en) * | 2021-01-22 | 2023-11-29 | Alexion Pharmaceuticals, Inc. | Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
JP5815403B2 (ja) | 2008-08-05 | 2015-11-17 | ノバルティス アーゲー | 補体タンパク質c5を標的とする抗体に関する組成物および方法 |
US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
WO2014099546A1 (en) | 2012-12-19 | 2014-06-26 | Promerus, Llc | Process for the preparation of high purity norbornene alkanols and derivatives thereof |
NZ711451A (en) * | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
KR102515796B1 (ko) | 2014-12-19 | 2023-03-30 | 추가이 세이야쿠 가부시키가이샤 | 항-c5 항체 및 그의 사용 방법 |
US20190135903A1 (en) * | 2015-03-31 | 2019-05-09 | Alexion Pharmaceuticals, Inc. | Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients |
JP6650042B2 (ja) * | 2015-12-27 | 2020-02-19 | アッヴィ・インコーポレイテッド | 装着型自動注射装置ならびに関連する組立方法および使用方法 |
US20190023775A1 (en) * | 2016-01-11 | 2019-01-24 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
AU2017283470B2 (en) | 2016-06-14 | 2024-03-21 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibodies and uses thereof |
SI3658184T1 (sl) * | 2017-07-27 | 2024-01-31 | Alexion Pharmaceuticals, Inc., | Formulacije z visoko koncentracijo protiteles proti-C5 |
KR20200070355A (ko) * | 2017-10-26 | 2020-06-17 | 알렉시온 파마슈티칼스, 인코포레이티드 | 발작성 야간 혈색소뇨 (pnh) 및 비정형 용혈성 요독 증후군 (ahus)의 치료를 위한 항-c5 항체의 투여량 및 투여 |
EP3802593A1 (en) * | 2018-05-31 | 2021-04-14 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
-
2019
- 2019-10-30 AU AU2019370295A patent/AU2019370295A1/en active Pending
- 2019-10-30 CA CA3118282A patent/CA3118282A1/en active Pending
- 2019-10-30 EA EA202191189A patent/EA202191189A1/ru unknown
- 2019-10-30 EP EP19806353.9A patent/EP3873602B1/en active Active
- 2019-10-30 JP JP2021519110A patent/JP2022512632A/ja active Pending
- 2019-10-30 MX MX2021004994A patent/MX2021004994A/es unknown
- 2019-10-30 EP EP23200753.4A patent/EP4306128A3/en active Pending
- 2019-10-30 WO PCT/US2019/058846 patent/WO2020092549A1/en unknown
- 2019-10-30 US US17/289,178 patent/US20210395352A1/en active Pending
- 2019-10-30 KR KR1020217015554A patent/KR20210084533A/ko unknown
- 2019-10-30 BR BR112021008063-5A patent/BR112021008063A2/pt unknown
- 2019-10-30 CN CN201980070341.7A patent/CN112996561A/zh active Pending
-
2021
- 2021-04-02 IL IL281990A patent/IL281990A/en unknown
- 2021-05-13 CO CONC2021/0006290A patent/CO2021006290A2/es unknown
-
2023
- 2023-11-24 JP JP2023199206A patent/JP2024015045A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3118282A1 (en) | 2020-05-07 |
CN112996561A (zh) | 2021-06-18 |
CO2021006290A2 (es) | 2021-06-10 |
WO2020092549A1 (en) | 2020-05-07 |
EP3873602A1 (en) | 2021-09-08 |
AU2019370295A1 (en) | 2021-06-03 |
KR20210084533A (ko) | 2021-07-07 |
IL281990A (en) | 2021-05-31 |
BR112021008063A2 (pt) | 2021-08-10 |
JP2022512632A (ja) | 2022-02-07 |
JP2024015045A (ja) | 2024-02-01 |
MX2021004994A (es) | 2021-06-15 |
EP4306128A3 (en) | 2024-03-27 |
EP3873602B1 (en) | 2023-12-06 |
EP4306128A2 (en) | 2024-01-17 |
US20210395352A1 (en) | 2021-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019022972A2 (pt) | Fomulações estáveis de anticorpos de receptor de morte programada 1 (pd-1) e métodos de uso das mesmas | |
EA202191189A1 (ru) | Подкожное введение и дозировка антител к c5 для лечения пароксизмальной ночной гемоглобинурии (пнг) | |
RU2011104955A (ru) | Композиции антител | |
MD3883606T2 (ro) | Metodă sigură și eficientă de tratament al colitei ulcerative cu anticorpi anti-IL12/IL23 | |
CO2020004831A2 (es) | Dosis y administración de anticuerpos antic-c5 para el tratamiento de pacientes con glomerulonefritis membranoproliferativa | |
EA202091810A1 (ru) | Антитела к b7-h4 и способы их применения | |
NZ601111A (en) | Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies | |
MX2020009265A (es) | Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23. | |
EA201890182A1 (ru) | Терапевтическое средство для лечения синдрома гунтера и способ его лечения | |
MX2020008730A (es) | Regímenes de dosificación de anticuerpo b7-h4. | |
EA201692126A1 (ru) | Способ достижения безлекарственной ремиссии у субъектов с ранним ревматоидным артритом (ra, ра) | |
MX2022013923A (es) | Metodos para tratar la enfermedad de crohn con el anticuerpo especifico anti-il23. | |
EA201991283A1 (ru) | Фармацевтическая композиция для предотвращения опиоидной зависимости | |
MX2022001153A (es) | Regimen de dosificacion y administracion para el tratamiento o prevencion de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab. | |
EA202090544A1 (ru) | Способ лечения заболевания, связанного с tnf- | |
EA202191273A1 (ru) | Применение тивозаниба для лечения субъектов с рефрактерным раком | |
EA202091036A1 (ru) | ДОЗИРОВАНИЕ И ВВЕДЕНИЕ АНТИТЕЛ ПРОТИВ C5 ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ С ПАРОКСИЗМАЛЬНОЙ НОЧНОЙ ГЕМОГЛОБИНУРИЕЙ (PNH) И АТИПИЧНЫМ ГЕМОЛИТИКО-УРЕМИЧЕСКИМ СИНДРОМОМ (aHUS) | |
EA202090894A1 (ru) | Дозирование и введение антител против c5 для лечения пациентов с мембранопролиферативным гломерулонефритом | |
EA202191388A1 (ru) | Лечение головной боли при избыточном применении лекарственных препаратов антителами к cgrp или cgrp-r | |
MX2022003668A (es) | Metodos y composiciones para el tratamiento de la retinopatia diabetica. | |
Ntanasis-Stathopoulos et al. | P57 PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA | |
EA202191581A1 (ru) | Неотложное лечение и быстрое лечение головной боли с использованием антител к cgrp | |
UA118991U (uk) | Спосіб дозування сечовини для проведення швидкого уреазного тесту у хворих на хронічний гелікобактеріоз | |
ÇETİN et al. | Bağımlılık Rehabilitasyonu | |
Nkatta-Abongwa | Evidence-based Educational Strategies to Increase Adolescent Human Papillomavirus (HPV) Vaccine Uptake: a Provider Approach |